Dr. Roopa Nath has over 15 years of academic and industry experience in Biotechnology. She holds a Ph.D. in yeast genomics from the University of Tennessee, Memphis and a B.Sc. in Biological Sciences from St. Xavier's college, Mumbai, India. Dr. Nath's most recent role is Senior Director of Global Technology Development at Actis Biologics, Inc., where she helped set up, build and grow the company's India operations. At Actis, Dr. Nath serves as key liaison between the India-based R&D team and the U.S. based Business Development and Technology Licensing team, and also plays an instrumental role in attracting, recruiting, training and mentoring new hires. Roopa's previous roles include an array of consulting engagements focused on the Indo-US business corridor. Her clients included global corporations such as Ernst & Young (now Cap Gemini), Persistent Systems and Kanbay, Inc. She is well connected within the Pharmaceutical and Business networks in the San Francisco Bay Area and India.

James manages Invitrogen’s bioinformatics software business globally, with a focus on end-user scientific applications for molecular and cellular biologists. He has been responsible for several major releases of Invitrogen’s flagship Vector NTI® sequence analysis software platform, and in 2005 he pioneered the company’s Open Access policy in the non-profit research segment, leading to a massive increase in Invitrogen’s user base, and revenue growth in new e-commerce channels. His ongoing focus is to develop innovative business models in the bioinformatics space. James previously held positions in sales, marketing and product management with InforMax, Inc., which was acquired by Invitrogen in 2003. Prior to joining InforMax, his research focus was in mammalian signal transduction, and the molecular genetics of HIV.

Dr. Stella Clark is CEO of the Bio21 Cluster, a health sciences/biotechnology cluster of research institutions which facilitates collaboration to maximise opportunities from Melbourne’s biomedical research strengths and translate them into outcomes that address issues related to human health and disease. Prior management experience was as General Manager, School of Graduate Studies, University of Melbourne and Scientific Executive Officer at the Baker Medical Research Institute. Before this she was an active biomedical research scientist in the area of diabetes. After gaining a PhD from the University of Melbourne in 1984, Stella spent three years as a CJ Martin Fellow at the Imperial Cancer Research Fund in London before returning to a research career in Australia. Her involvement on the Board and Executive of the Australian Society for Medical Research, culminating as President (1995), heightened her interest in broader aspects of medical research including politics, policy and PR and led to her move into research management. In 2000, Stella was President of the Australasian Research Management Society.
In 1994, Stella helped establish the Premier’s Award for Medical Research, which recognises outstanding talent amongst young Victorian medical researchers. In 1997 Stella was appointed to the National Health and Medical Research Council and in 1998 became an Honorary Fellow of Museum Victoria. Stella completed the Williamson Community Leadership program in 1997 and is a Fellow of Leadership Victoria where she is an active participant in Leadership Victoria Skillsbank. She is currently Chair of the Leadership Victoria Skillsbank Advisory team and a Director & Member of Council for Leadership Victoria. Stella is also a Director and Honorary Secretary of the BioMelbourne Network and a Director of the Victorian Public Health Research and Education Council.

Julie Hughes has 17 years of experience in the information management industry and has been with Pfizer since 2004. She leads a technology group within the Pharmaceutical Sciences Global Biologics organization.
This group is responsible for the integration of analytical technology with the informatics technology to support the development of drug candidates. Currently Julie's group is working with other Pharmaceutical Science colleagues to implement various Pharmaceutical Science / IT Projects including a Data Archival System, a Chromatography Data System, a Laboratory Information Management System, and an Electronic Laboratory Notebook System. The goal of these projects is to integrate the analytical technology with the informatics technology.

Mr. Kisler has over 20 years of technical and business experience from both the public and private sectors. He has worked in the pharmaceutical industry for the past 12 years, focusing on development of innovative clinical research and healthcare technology solutions.
He co-founded the Clinical Data Interchange Standards Consortium (CDISC) in 1997 and currently serves as Director, Terminology & Strategic Alliances. Mr. Kisler oversees the CDISC Terminology Program where he is responsible for development, harmonization and publication of controlled terminology standards for clinical research. He has forged important strategic alliances on behalf of CDISC, most notably those with the US National Cancer Institute (NCI), professional societies such as the American College of Cardiology and other key organizations such as the Global Alliance for TB Drug Development.
In partnership with Duke Clinical Research Institute, Mr. Kisler helps oversee several key US National Institutes of Health projects, focused on development of data standards for Tuberculosis and Cardiovascular Disease. He is very active in coordinating joint standards development activities with other standards organizations such as ISO and Health Level Seven (HL7), where he has served as co-chair for a number of technical committees. Most recently, Mr. Kisler was selected to participate on the Technical Harmonization Committee for BRIDG – The Biomedical Research Integrated Domain Group.
Mr. Kisler is a graduate of the University of Central Florida in Orlando and holds 3 Bachelor of Science degrees in Mathematics, Computer Science and Statistics.

Mafruz Zaman Ashrafi is currently a Research Fellow at the Data Mining Department, Institute for Infocomm Research. He holds a PhD in Computer Science from Monash University, Australia, and received his Ph.D. degree in 2006. His research interests include Data Mining and Privacy and Security. He has been serving as a member of Editorial Review Board (ERB) of the "Advances in Data Warehousing and Mining" Book Series published by IGI Press, Inc (USA).

Ms. Julie Olszewski has 17 years experience in the global Pharmaceutical Industry, focusing on Research and Development of novel medicines. Building on her scientific background in Pharmacology and Toxicology, she has contributed in many aspects of drug discovery including Basic Research, Clinical Information Technology and most recently Clinical Data Management.
As part of the global operations of Merck & Co. Inc, Whitehouse Station, New Jersey, USA, Julie has been based out of offices in the USA, Europe and Japan. She is currently living in Beijing, China. These opportunities have given her a unique perspective on the challenges of integrating clinical study data worldwide. She has shared her ideas on this topic at major Pharmaceutical Industry meetings in the US and China.
Julie is a dedicated advocate of combining the best technology available with an efficient process to bring medicines to patients sooner. She strongly believes that companies need to recognize their clinical study information as a valuable asset essential to their success.

Harsukh completed his medical training at Aberdeen University Medical School in 1980 and post-graduate specialist clinical, academic and research training in general internal medicine, immunology, respiratory medicine and oncology at various teaching hospitals in London including St Bartholomew, Westminster & Charing Cross Hospitals, London (Imperial Medical School, one of the top 3 biomedical institutions in the world).
He joined Pfizer Central Research in 1994 in the Dept of Experimental Medicine as Clinical Project Manager/Associate Director and worked on various anti-bacterial, anti-fungal, cardiovascular and oncology projects and later joined Roche Global Drug Development as Global Clinical Science Leader, Director of Oncology and worked on various projects in oncology, virology, asthma and allergy. Since 1998 he has been Director, Global Experimental Medicine, R & D Charnwood and in 2003 took on the additional role of Director, Global Discovery Medicine, Respiratory & Inflammation Therapeutic Area and has had responsibility within his department for various projects in Cardiovascular, Respiratory (Asthma, Rhinitis, COPD) and Inflammation (Rheumatoid arthritis, Osteoarthritis, Transplantation and Psoriasis).

Dr. Michael Shi is currently the Director and Biomarker Project Leader in Exploratory Oncology Development at Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA. In his current role, Dr. Shi provides scientific and strategic leadership in biomarker development to support Novartis oncology drug development. Before joining Novartis, Dr. Shi worked extensively in the areas of biomarker development, molecular profiling and pharmacogenomics to support drug discovery and development at Merck & Co., Pfizer, Inc. and Sequenom, Inc. He also served as the director of the Genetics Variation Program at NIH and an assistant professor of pathology at the University of Michigan. Dr. Shi received his medical education from Perking Union Medical College (Beijing, China), a Ph.D. in Molecular Pharmacology and Toxicology from the University of Southern California (Los Angeles, USA) and conducted a postdoctoral fellowship at Harvard Medical School (Boston, USA).

Dr Victor Tong currently serves as Principal Investigator of Molecular Design Group and Assistant Department Head of Data Mining Department at Institute for Infocomm Research, A*STAR, Singapore. He is also the immediate past vice-president of the Association for Medical and Bio-Informatics, Singapore (AMBIS). Dr Tong's current research focuses on computational modeling and analysis of immunological data, virtual screening, virtual library design and data warehousing.

John is the author of numerous articles on Japan's healthcare system, and has been with the Kameda Medical Center since 1991, and currently is the Executive Vice President for Administration as well as the Director, International Affairs and International Patient Services. The Kameda Medical Center is an 802 bed private teaching hospital, with a freestanding ambulatory care center which averages more than 3000 outpatient visits per day. Kameda achieved full ISO9001 certification in March of 2001, was ranked 4/100 by Nikkei Publications in 2001, and 5/100 by Weekly Asahi in October of 2002. In 2006 Trendy Magazine ranked Kameda #1. Kameda is additionally accredited by the British Standards Institute, The United Kingdom Accrediting Services, the Japan Accrediting Board, and the Japan Information Processing Development Corporation (Privacy Mark Certified). In 2007 Kameda won a “Best Wired” hospital award for Information technology, and a “Best Practice” hospital award from the Bertlesmann Foundation. John has a Master's Degree in Healthcare Administration from Baylor University and is a Fellow in the American College of Healthcare Executives. He has undergraduate degrees from the University of Maryland in Japanese Studies and Asian Studies. As a Preceptor for the University of Iowa's Graduate Program in Hospital and Health Services Administration, John has mentored 17 graduate students from that program who completed three-month summer internships at Kameda. He wrote a book, translated into Japanese, intended as a patient's guide to hospitalization in Japan, published by Nikkei Book Publishing Company, in October of 2000 – “Nippon no Byoin” In February of 2003, his second book – Patient Safety Guide to Hospitalization was published in Korea (in Hangul).

Dr Grace Wong has worked for Genentech, Millennium, AstraZeneca and Serono on new drug discovery in a variety of therapeutic areas for many years. Dr. Wong earned a PhD at WEHI in Australia, and a postdoc with Dr. David Goeddel at Genentech and advanced basic research discoveries to product development. In 1996, Dr. Wong became the Head of Apoptosis Research at Millennium Pharmaceuticals, worked at AstraZeneca as Section Head of Molecular Genetics and at Serono as Head of Functional Genomics. She has been awarded 13 scholarships from Australian and American organizations and received 5 Recognition Awards from Genentech.
Dr. Wong has been invited to give presentations at 153 international conferences including the Nobel Symposium (Sweden, 1994). She has published 93 papers and filed 28 patents. Some of her publications (3 Nature, 1 Science, 3 Cell, 5 PNAS, and 7 J. Immunol) have received 300-1000 citations. Dr. Wong has founded Actokine Therapeutics (www.actokine.com) for new drug advancements for cancer, obesity, CNS, woman diseases and emerging viral diseases. She also founded Student Vision (www.studentvision.org) and the Nobel Pauling Symposia (www.pauling.us) to help students of all ages in biotechnology.